Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 39

1.

A role for corticotropin-releasing factor signaling in the lateral habenula and its modulation by early-life stress.

Authement ME, Langlois LD, Shepard RD, Browne CA, Lucki I, Kassis H, Nugent FS.

Sci Signal. 2018 Mar 6;11(520). pii: eaan6480. doi: 10.1126/scisignal.aan6480.

2.

Anhedonia Following Early-Life Adversity Involves Aberrant Interaction of Reward and Anxiety Circuits and Is Reversed by Partial Silencing of Amygdala Corticotropin-Releasing Hormone Gene.

Bolton JL, Molet J, Regev L, Chen Y, Rismanchi N, Haddad E, Yang DZ, Obenaus A, Baram TZ.

Biol Psychiatry. 2018 Jan 15;83(2):137-147. doi: 10.1016/j.biopsych.2017.08.023. Epub 2017 Sep 7.

3.

Shank is a dose-dependent regulator of Cav1 calcium current and CREB target expression.

Pym E, Sasidharan N, Thompson-Peer KL, Simon DJ, Anselmo A, Sadreyev R, Hall Q, Nurrish S, Kaplan JM.

Elife. 2017 May 6;6. pii: e18931. doi: 10.7554/eLife.18931.

4.

Disrupted-in-Schizophrenia-1 is essential for normal hypothalamic-pituitary-interrenal (HPI) axis function.

Eachus H, Bright C, Cunliffe VT, Placzek M, Wood JD, Watt PJ.

Hum Mol Genet. 2017 Jun 1;26(11):1992-2005. doi: 10.1093/hmg/ddx076.

5.

Corticotropin-releasing hormone and dopamine release in healthy individuals.

Payer D, Williams B, Mansouri E, Stevanovski S, Nakajima S, Le Foll B, Kish S, Houle S, Mizrahi R, George SR, George TP, Boileau I.

Psychoneuroendocrinology. 2017 Feb;76:192-196. doi: 10.1016/j.psyneuen.2016.11.034. Epub 2016 Dec 1.

PMID:
27951520
6.

Variable telomere length across post-mortem human brain regions and specific reduction in the hippocampus of major depressive disorder.

Mamdani F, Rollins B, Morgan L, Myers RM, Barchas JD, Schatzberg AF, Watson SJ, Akil H, Potkin SG, Bunney WE, Vawter MP, Sequeira PA.

Transl Psychiatry. 2015 Sep 15;5:e636. doi: 10.1038/tp.2015.134. Erratum in: Transl Psychiatry. 2016 Dec 6;6(12 ):e969.

8.

Corticotropin-releasing hormone and the hypothalamic-pituitary-adrenal axis in psychiatric disease.

Naughton M, Dinan TG, Scott LV.

Handb Clin Neurol. 2014;124:69-91. doi: 10.1016/B978-0-444-59602-4.00005-8. Review.

PMID:
25248580
9.

Stress and neurodevelopmental processes in the emergence of psychosis.

Holtzman CW, Trotman HD, Goulding SM, Ryan AT, Macdonald AN, Shapiro DI, Brasfield JL, Walker EF.

Neuroscience. 2013 Sep 26;249:172-91. doi: 10.1016/j.neuroscience.2012.12.017. Epub 2013 Jan 5. Review.

10.

Immune system and glucose metabolism interaction in schizophrenia: a chicken-egg dilemma.

Steiner J, Bernstein HG, Schiltz K, Müller UJ, Westphal S, Drexhage HA, Bogerts B.

Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jan 3;48:287-94. doi: 10.1016/j.pnpbp.2012.09.016. Epub 2012 Oct 17. Review.

PMID:
23085507
11.

Genetic load is associated with hypothalamic-pituitary-adrenal axis dysregulation in macaques.

Ferguson B, Hunter JE, Luty J, Street SL, Woodall A, Grant KA.

Genes Brain Behav. 2012 Nov;11(8):949-57. doi: 10.1111/j.1601-183X.2012.00856.x. Epub 2012 Oct 13.

12.

Quetiapine affects neuropeptide Y and corticotropin-releasing hormone in cerebrospinal fluid from schizophrenia patients: relationship to depression and anxiety symptoms and to treatment response.

Nikisch G, Baumann P, Liu T, Mathé AA.

Int J Neuropsychopharmacol. 2012 Sep;15(8):1051-61. doi: 10.1017/S1461145711001556. Epub 2011 Oct 19.

PMID:
22008251
13.

Stress and anxiety in schizophrenia and depression: glucocorticoids, corticotropin-releasing hormone and synapse regression.

Bennett A O MR.

Aust N Z J Psychiatry. 2008 Dec;42(12):995-1002. doi: 10.1080/00048670802512073. Review.

PMID:
19016087
14.

Association of HPA axis genes with suicidal behaviour in schizophrenia.

De Luca V, Tharmalingam S, Zai C, Potapova N, Strauss J, Vincent J, Kennedy JL.

J Psychopharmacol. 2010 May;24(5):677-82. doi: 10.1177/0269881108097817. Epub 2008 Oct 6.

PMID:
18838498
15.

Role of metabotropic glutamate receptors in the control of neuroendocrine function.

Durand D, Pampillo M, Caruso C, Lasaga M.

Neuropharmacology. 2008 Sep;55(4):577-83. doi: 10.1016/j.neuropharm.2008.06.022. Epub 2008 Jun 20. Review.

PMID:
18616955
16.

Synaptic physiology of central CRH system.

Gallagher JP, Orozco-Cabal LF, Liu J, Shinnick-Gallagher P.

Eur J Pharmacol. 2008 Apr 7;583(2-3):215-25. doi: 10.1016/j.ejphar.2007.11.075. Epub 2008 Feb 1. Review.

17.

Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study.

McCreadie RG; Scottish Schizophrenia Lifestyle Group.

Br J Psychiatry. 2003 Dec;183:534-9.

PMID:
14645025
18.

Spontaneous dyskinesia in first-degree relatives of chronically ill, never-treated people with schizophrenia.

McCreadie RG, Thara R, Srinivasan TN, Padmavathi R.

Br J Psychiatry. 2003 Jul;183:45-9.

PMID:
12835243
19.

The role of peptides in treatment of psychiatric disorders.

Holsboer F.

J Neural Transm Suppl. 2003;(64):17-34. Review.

PMID:
12830927
20.

Neuropeptides involved in the pathophysiology of schizophrenia and major depression.

De Wied D, Sigling HO.

Neurotox Res. 2002 Aug-Sep;4(5-6):453-468.

PMID:
12754159

Supplemental Content

Loading ...
Support Center